-

11:26:50 PM

AEMD Stock News

AEMD - Aethlon Medical Inc

10/12/21 8:01 AM

Nasdaq : AEMD

covid-19

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of

RHEA-AI

neutral

09/30/21 8:02 AM

Nasdaq : AEMD, PPD

Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research

RHEA-AI

neutral

09/07/21 8:01 AM

Nasdaq : AEMD

conferences

Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23 rd Annual Global Investment

RHEA-AI

neutral

08/09/21 4:15 PM

Nasdaq : AEMD

earnings

Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on

RHEA-AI

neutral

07/29/21 1:32 PM

Nasdaq : AEMD

earnings

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday,

RHEA-AI

neutral

06/24/21 4:15 PM

Nasdaq : AEMD

earnings

Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2021 and provided an update on

RHEA-AI

neutral

06/21/21 3:27 PM

Nasdaq : AEMD

earnings

Aethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET on

RHEA-AI

neutral

06/10/21 9:10 AM

Nasdaq : AEMD

offering

Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct

RHEA-AI

neutral

06/03/21 8:01 AM

Nasdaq : AEMD

covid-19

Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the

RHEA-AI

neutral

03/01/21 8:02 AM

Nasdaq : AEMD

conferences

Aethlon Medical to Participate in Two Upcoming Healthcare Investor Conferences

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that the company will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and the

RHEA-AI

neutral